Horizon Discovery, H3 Bio Launch Screening Program for Oncology Targets | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery and H3 Biomedicine today launched SyntheTx, a technology partnership created to provide novel oncology targets and early-stage drug discovery programs to drug manufacturers.

H3 Biomedicine, a Cambridge, Mass.-based biopharmaceutical firm, is the first partner in the program. Additional partners will be sought in the first 12 to 18 months of the program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Apr
11
Sponsored by
Personal Genome Diagnostics

This webinar will provide an overview of genomic alterations that play a role in immunotherapy response.

May
04
Sponsored by
Qiagen

This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

May
23
Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants.